Alkem Laboratories Ltd.

NSE: ALKEM BSE: 539523 SECTOR: Pharmaceuticals & Drugs  49k   416   62

3550.70
+24.05 (0.68%)
NSE: 21 Jan 03:57 PM

Price Summary

Today's High

₹ 3574.9

Today's Low

₹ 3454.55

52 Week High

₹ 4070

52 Week Low

₹ 2540.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

42453.94 Cr.

Enterprise Value

42119.74 Cr.

No. of Shares

11.96 Cr.

P/E

23.7

P/B

4.94

Face Value

₹ 2

Div. Yield

0.84 %

Book Value (TTM)

₹  718.54

CASH

1673.36 Cr.

DEBT

1339.16 Cr.

Promoter Holding

57.13 %

EPS (TTM)

₹  149.79

Sales Growth

8.13%

ROE

24.23 %

ROCE

23.42%

Profit Growth

33.27 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alkem Laboratories Ltd.

CLAVAM TAXIM Livoerb Pregakem PLAYGARD CONDOMS

Index Presence

The company is present in 28 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.13%
3 Year10.99%
5 Year13.35%

Profit Growth

1 Year33.27%
3 Year33.03%
5 Year19.2%

ROE%

1 Year24.23%
3 Year20.41%
5 Year19.75%

ROCE %

1 Year23.42%
3 Year20.31%
5 Year20.18%

Debt/Equity

0.1756

Price to Cash Flow

32.05

Interest Cover Ratio

44.8923829489867

CFO/PAT (5 Yr. Avg.)

0.667248155502455

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2021 57.13 0
Sep 2021 58.84 0
Jun 2021 58.84 0
Mar 2021 60.16 0
Dec 2020 62.43 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 33.0254858799963% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.406656832087% over the past 3 years.
  • Company has been maintaining healthy ROCE of 20.313370602394% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 44.8923829489867.
  • The Company has been maintaining an effective average operating margins of 20.1263308294546% in the last 5 years.
  • Company’s PEG ratio is 0.712496278985985.
  • The company has an efficient Cash Conversion Cycle of 75.8894057658769 days.
  • The company has a high promoter holding of 58.84%.

 Limitations

  • The company has shown a poor revenue growth of 10.9856899632051% for the Past 3 years.
  • Tax rate is low at 10.5726264395266.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 1984.1 1778.75 1917.47 2278.67 2363.99
Total Expenditure 1389.83 1335.58 1501.06 1728.1 1776.15
Operating Profit 594.27 443.17 416.41 550.57 587.84
Other Income 24.84 72.46 48.77 39.21 43.21
Interest 14.76 8.77 7.36 9.06 8.5
Depreciation 51.62 50.08 49.38 51.72 53.82
Exceptional Items 0 0 -12.78 0 0
Profit Before Tax 552.73 456.78 395.66 529 568.73
Tax 57.53 55.8 32.92 59.73 10.72
Profit After Tax 495.2 400.98 362.74 469.27 558.01
Adjusted EPS (Rs) 41.42 33.54 30.34 39.25 46.68

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 4548.23 5281.01 5714.09 6677.08 7219.68
Total Expenditure 3670.24 4307.61 4668.38 5209.43 5270.75
Operating Profit 877.99 973.4 1045.71 1467.65 1948.93
Other Income 116.6 100.91 67.58 95.98 190.01
Interest 23.68 32.37 28.26 38.71 42.93
Depreciation 76.48 107.65 141.07 186.84 198.93
Exceptional Items 0 0 0 0 -12.78
Profit Before Tax 894.43 934.29 943.96 1338.08 1884.3
Tax 11.27 218.45 144.12 73.66 199.22
Net Profit 883.16 715.84 799.84 1264.42 1685.08
Adjusted EPS (Rs.) 73.87 59.88 66.9 105.77 140.95

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 23.91 23.91 23.91 23.91 23.91
Total Reserves 4368.74 4861.45 5441.3 6256.53 7601.84
Borrowings 0 6.33 6.32 6.32 6.32
Other N/C liabilities -498.65 -442.25 -485.84 -579.85 -723.71
Current liabilities 1413.35 1786.68 1669.87 2579.76 2909.94
Total Liabilities 5307.35 6236.12 6655.56 8286.67 9818.3
Assets
Net Block 1125.63 1470.99 1606.38 1836.76 1758.36
Capital WIP 218.44 298.92 381.59 313.66 323.26
Intangible WIP 0 0 0 0 0
Investments 1225.64 1203.42 1476.42 1794.52 1990.21
Loans & Advances 179.23 205.67 93.92 107.61 110.04
Other N/C Assets 290.38 25.43 16.57 4.94 4.89
Current Assets 2268.03 3031.69 3080.68 4229.18 5631.54
Total Assets 5307.35 6236.12 6655.56 8286.67 9818.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 894.43 934.29 943.96 1338.08 1884.3
Adjustment -3.93 77.39 130.06 141.24 123.34
Changes in Assets & Liabilities -186.67 -512.07 -124.43 -563.6 -361.86
Tax Paid -204.77 -181.35 -204.5 -233.94 -321.3
Operating Cash Flow 499.06 318.26 745.09 681.78 1324.48
Investing Cash Flow -361.9 -273.11 -313.06 -995.17 -1120.99
Financing Cash Flow -124.64 -59.98 -275.75 172.64 -208.96
Net Cash Flow 12.52 -14.83 156.28 -140.75 -5.47

Corporate Actions

Investors Details

PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Promoters 62.43 60.16 58.84 58.84 57.13
sarandhar singh (s... 21.08 - - - -
sarandhar singh* (... - 21.08 21.08 21.08 -
dhananjay kumar si... 6.24 7.96 7.96 7.96 -
basudeo narain sin... 7.24 7.24 7.24 7.24 -
mritunjay kumar si... 6.38 6.38 6.38 6.38 -
jayanti sinha 5.97 5.97 5.97 4.30 -
madhurima singh 2.49 - - - -
madhurima singh - 0.76 0.76 0.76 -
seema singh 2.46 2.46 2.46 2.46 -
lalan kumar singh - - - - -
archana singh 2.00 2.00 2.00 2.00 -
samprada singh 1.32 - - - -
meghna singh 1.01 1.01 1.01 1.01 -
divya singh 1.01 1.01 1.01 1.01 -
aniruddha singh 1.00 1.01 1.01 1.01 -
shrey shree anant ... 1.00 1.00 1.00 1.00 -
raj kumar singh 0.45 0.45 0.45 0.45 -
samprada singh huf 0.13 0.13 0.13 - -
balmiki prasad sin... - 0.06 0.06 0.10 -
sandeep singh# (pl... - 0.09 0.09 0.09 -
sandeep singh# (th... 0.09 - - - -
srinivas singh# (t... 0.07 - - - -
sarvesh singh# (t... 0.07 - - - -
sarandhar singh# (... 0.07 - - - -
sarandhar singh# (... - 0.07 0.07 0.07 -
srinivas singh# (p... - 0.07 0.07 0.07 -
sarvesh singh# (p... - 0.07 0.07 0.07 -
satish kumar singh... - 0.02 0.02 0.06 -
balmiki prasad sin... 0.06 - - - -
satish kumar singh... 0.02 - - - -
inderjit kaur aror... - 0.01 0.01 0.01 -
inderjit kaur aror... 0.01 - - - -
PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Investors 37.57 39.84 41.16 41.16 42.87
tushar kumar - sha... - - - - 6.30
life insurance cor... 3.97 3.97 4.05 4.23 -
nawal kishore singh 2.37 2.50 2.17 2.21 -
deepak kumar singh 2.46 2.46 2.45 2.43 2.87
kishor kumar singh 2.86 2.86 2.86 2.86 2.86
rajesh kumar 2.71 2.71 2.71 2.71 2.76
rajeev ranjan 2.54 2.54 2.54 2.54 2.54
sbi equity hybrid ... 1.50 1.35 - - -
alok kumar . 1.18 1.18 2.31 2.31 -
ashok kumar 1.17 1.17 2.31 2.31 1.17
maya devi 2.27 2.27 - - -
icici prudential p... 1.21 1.97 2.06 1.86 -
dsp midcap fund 1.18 1.48 1.48 1.47 -
hdfc life insuranc... - - - - -
alok kumar - - - - 1.18
motilal oswal most... - - - - 1.02
llp - 0.01 0.02 0.01 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Alkem Laboratories to launch unique patented technology for treatment of Diabetic Foot Ulcer12 Jan 2022, 12:45PM Alkem Laboratories informs about related party transactions30 Nov 2021, 4:52PM Alkem Laboratories informs about demise of MD28 Oct 2021, 1:15PM Alkem Laboratories informs about disclosure 20 Sep 2021, 1:34PM Alkem Laboratories gets nod to close operations at Baddi facility20 Sep 2021, 12:44PM Alkem Laboratories reports 11% rise in Q1 consolidated net profit7 Aug 2021, 11:25AM Alkem Laboratories launches Ibuprofen and Famotidine Tablets in United States4 Aug 2021, 10:31AM Alkem Laboratories informs about press release4 Aug 2021, 10:14AM USFDA concludes inspection at Alkem Laboratories’ Bioequivalence Center at Taloja30 Jul 2021, 9:42AM Alkem Laboratories looking at partnerships, in-licensing deals in US19 Jul 2021, 9:03AM Alkem Laboratories informs about newspaper advertisement17 Jul 2021, 2:18PM Alkem Laboratories launches Perampil tablets10 Jun 2021, 3:25PM Alkem Laboratories agrees to subscribe to partnership interest in ABCD Technologies LLP30 Mar 2021, 12:48PM Alkem Laboratories agrees to partner with Tata Memorial Centre 23 Mar 2021, 12:50PM Alkem Laboratories informs about press release15 Mar 2021, 3:14PM Alkem Laboratories launches Brivasure15 Mar 2021, 2:55PM Alkem Laboratories informs about disclosure3 Dec 2020, 3:23PM Alkem Laboratories informs about postal ballot notice27 Nov 2020, 1:20PM Alkem Laboratories informs about opening of trading window7 Aug 2020, 3:27PM Alkem Laboratories launches Favipiravir for COVID-19 treatment 6 Aug 2020, 9:12AM Alkem Laboratories gets EIR for St Louis facility13 May 2020, 2:17PM

Alkem Laboratories Stock Price Analysis and Quick Research Report. Is Alkem Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alkem Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1324.48 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alkem Laboratories has a Debt to Equity ratio of 0.1756 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alkem Laboratories , the EPS growth was 33.2690087154585 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alkem Laboratories has OPM of 26.9946867451189 % which is a good sign for profitability.
     
  • ROE: Alkem Laboratories have a healthy ROE of 24.234962991301 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Alkem Laboratories

X